期刊文献+

唑来膦酸联合放疗治疗恶性肿瘤骨转移疼痛 被引量:4

Effect of treatment on metastatic bone tumour with zoledronic acid and radiotherapy
下载PDF
导出
摘要 目的观察唑来膦酸联合放疗与单纯药物治疗恶性肿瘤骨转移癌性疼痛的疗效及不良反应。方法40例骨转移瘤患者随机分为A、B两组(各20例)。A组静滴唑来膦酸4 m g;B组静滴唑来膦酸4 m g后局部放疗。结果两组止痛效果比较:A组显效2例,有效12例,无效6例;B组分别为12、7、1例;两组比较,P<0.05。止痛起效时间:A组为(7.2±2.0)d;B组为(3.0±1.2)d;两组比较,P<0.05。两组均无严重不良反应。结论唑来膦酸联合放疗对恶性肿瘤骨转移所致的癌性疼痛具有良好的止痛效果。 [Objective] To evaluate the efficacy and side effect ot' zoledronic acid and radiotherapy to relieve pain due to metastatic bone tumours. [Methods] 40 patients with metastatic bone tumours were randomly divided into group A (n = 20) and group B (n = 20). Group A was treated with zometa (4 rag,iv drip). Group B was treated by zometa (4 mg,iv drip) and radiotherapy. [Results] The numbers of patients with remarkable effect , effect and no effect after treatment in group A were 2,12,6 cases;but in group B were 12,7,1 cases( P 〈 0.01) respectively. The average respond times were (7.2± 2.0)days in group A,and (3. 0±1.2)days in group B ( P 〈 0.05) respectively. The side effect was not serious in two groups. [Conclusion] Zometa can remit metastatic ostealgia effectively,zometa combined with radiation will be better. The side effect were slight and temporal.
出处 《山东医药》 CAS 北大核心 2007年第3期14-15,共2页 Shandong Medical Journal
关键词 唑来膦酸 放射疗法 骨转移瘤 癌性疼痛 zoledronic acid radiotherapy metastatic bone tumor
  • 相关文献

参考文献4

二级参考文献17

  • 1李淑芬,佟仲生,汪旭,何丽宏.博宁及博宁联合化疗治疗骨转移引起疼痛的临床观察[J].中国肿瘤临床,2004,31(21):1250-1252. 被引量:6
  • 2[2]Coleman RE,Purohit OP.Osteoclast inhibition for the treatment of bone metastases.Cancer Treat Rev,1993,19(2):79~203
  • 3[4]Lipton A, Samll E, Saad F, et al. The new bisphonate, Zometa (zoledronci acid) decreases skeletal complications in both lytic and blastic lestic lesions: a comparision to pamidronate. Cancer Invest 2001,20(1):45~47
  • 4[5]Lipton A, Costa L, Ali S, et al. Use of bone turnover for monitoring bone metastases and response to therapy. Semminars in Oncology, 2001, 28(4): 254~259
  • 5[6]Ralston SH, Patel U, Fraser WD, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet , 1989,20(2):180~182
  • 6[4]Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-bingding proteins, including Ras J Bone Miner Res, 1998, 13:581
  • 7[5]Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular molecular mechanisms of action of bisphophonates. Cancer,2000, 88 (Suppl) : 2961
  • 8[6]Benford HL, Helfrich MH, Sebti S, et al. Inhibition of protein geranylation by bisphosphonates and GGTI298 causes activation of caspase-3 like proteases in osteoclasts. Calcif Tissue Int, 1999,64 (Suppl) :45
  • 9[7]Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 429446, a new, potent, heterocyclinc bisphosphonate compound. J Bone Miner Res, 1994, 9:745
  • 10[8]Body JJ, Lortholary A, romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res, 1999, 14:1557

共引文献15

同被引文献26

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部